Low-grade Serous Ovarian Cancer
📧 Sign up to get email alerts when something new happens for Low-grade Serous Ovarian Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer [Phase 2]
A Phase 2 clinical trial is evaluating avutometinib, defactinib, and letrozole in patients with low-grade serous ovarian cancer and is curre…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer [Phase 3]
This clinical trial update notes that a Phase 3 study of Avutometinib in combination with Defactinib is underway for recurrent low-grade ser…
-
CLINICAL_TRIALS research · 2026-03-24Clinical Trial Update: Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 3]
This Phase 3 trial is evaluating letrozole with or without paclitaxel and carboplatin in stage II-IV ovarian, fallopian tube, or primary per…
-
CLINICAL_TRIALS research · 2026-03-10Clinical Trial Update: Phase I Trial of Defactinib and VS-6766. [Phase 1]
A Phase I clinical trial evaluating the combination of defactinib and VS-6766 across multiple solid tumors, including non-small cell lung ca…
-
CLINICAL_TRIALS research · 2025-12-03Clinical Trial Update: Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers [Phase 1, Phase 2]
Regeneron is conducting a Phase 1/2 trial of REGN4018 (Ubamatamab) alone or in combination with cemiplimab in adults with recurrent MUC16-ex…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-08-21Clinical Trial Update: Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer [Phase 2]
This Phase 2 clinical trial evaluates regorafenib in combination with fulvestrant for recurrent low-grade serous ovarian cancer and is curre…
-
CLINICAL_TRIALS research · 2025-06-15Clinical Trial Update: RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer [Phase 2]
Phase 2 trial RESOLVE is evaluating abemaciclib plus letrozole, with optional metformin, zotatifin, or gedatolisib, in endometrial cancer an…
-
CLINICAL_TRIALS research · 2025-05-23Clinical Trial Update: Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer [Phase 2]
An ongoing Phase 2 study evaluating pembrolizumab in combination with chemotherapy for platinum-sensitive recurrent low-grade serous ovarian…
-
CLINICAL_TRIALS research · 2025-01-29Clinical Trial Update: A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation [Phase 2]
Phase 2 study evaluating Avutometinib alone versus combination with Defactinib in recurrent low-grade serous ovarian cancer, including KRAS-…